Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

1,800

Participants

Timeline

Start Date

October 25, 2022

Primary Completion Date

April 10, 2023

Study Completion Date

April 10, 2023

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

Experimental 23-valent PPV

The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection.

BIOLOGICAL

Control 23-valent PPV

The control vaccine was manufactured by Merck Sharp \& Dohme, Ltd. Purified capsular polysaccharides from 23 Streptococcus in 0.5 mL of pneumoniae types 0.25% phenol and sodium chloride.

Trial Locations (1)

710000

Linwei District Center for Disease Control and Prevention, Weinan

All Listed Sponsors
lead

Sinovac Biotech Co., Ltd

INDUSTRY